Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16750982 | 0.84 | KDM4E (0.69) | KDM4EKMT2ACYP1A2CYP2D6 | |
| SCHEMBL8301886 | 0.83 | — | — | |
| SCHEMBL18012255 | 0.80 | KDM4E (0.64) | KDM4EKMT2ACYP1A2 | |
| SCHEMBL22679781 | 0.80 | KDM4E (0.53) | KDM4EKMT2ACYP1A2 | |
| SCHEMBL807124 | 0.80 | KDM4E (1.00) | KDM4EKMT2ACYP1A2 | |
| SCHEMBL13950739 | 0.78 | KDM4E (0.62) | KDM4EKMT2ACYP1A2 | |
| SCHEMBL10500056 | 0.78 | KDM4E (0.62) | KDM4EKMT2ACYP1A2 | |
| SCHEMBL23240873 | 0.78 | — | — | |
| SCHEMBL7806892 | 0.78 | KDM4E (0.40) | KDM4EKMT2ACYP1A2 | |
| SCHEMBL19996600 | 0.77 | KDM4E (0.55) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023150618-A2 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150630-A2 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| EP-3988108-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | Rhythm Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022067086-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3539551-B1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | RHYTHM PHARMACEUTICALS INC (US) | 2021-10-06 | — | — | EP | disclosed |
| US-20210163536-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA SAS (FR) | 2021-06-03 | — | — | US | disclosed |
| US-20200360483-A1 | METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | IPSEN PHARMA S.A.S. (FR) | 2020-11-19 | — | — | US | disclosed |
| WO-2019195756-A1 | COMPOSITIONS FOR TREATING KIDNEY DISEASE | RHYTHM PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20100184646-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA S.A.S. (FR) | 2010-07-22 | — | — | US | disclosed |
| WO-2009061411-A2 | USE MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA S.A.S. (FR) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009010733-A2 | PEPTIDE GAP JUNCTION MODULATORS | ZEALAND PHARMA A/S (DK) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008147556-A2 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA S.A.S. (FR) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008051421-A2 | PEPTIDE-CYTOTOXIC CONJUGATES | IPSEN PHARMA S.A.S. (FR) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008039415-A2 | ANALOGS OF GHRELIN SUBSTITUTED AT THE N-TERMINAL | IPSEN PHARMA S.A.S. (FR) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007106385-A2 | USE OF A GHRELIN AGONIST TO IMPROVE THE CATABOLIC EFFECTS OF GLUCOCORTICOID TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007041278-A2 | COMPOSITION AND METHODS FOR STIMULATING GASTROINTESTINAL MOTILITY | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007038678-A2 | ANALOGS OF GHRELIN | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2007-04-05 | — | — | WO | disclosed |
| WO-2004009616-A2 | GHRELIN ANALOGS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360483-A1 | METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | PROKR1, CCL2, PROKR2 | KDM4E 4127/4885KMT2A 3660/4885CYP1A2 4180/4885 |
| US-20210163536-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | KDM4E 2610/4885KMT2A 2039/4885CYP1A2 3128/4885 |
| US-20100184646-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | KDM4E 2610/4885KMT2A 2039/4885CYP1A2 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.